GPCR/G Protein

Fluphenazine enanthate is a long-acting injectable antipsychotic compound that primarily targets dopamine receptors. It is utilized in the treatment of schizophrenia, providing sustained therapeutic effects that assist in managing acute and chronic symptoms of the disorder. Researchers can explore its pharmacological properties and effects on neurotransmitter dynamics in various experimental models related to psychosis and mental health disorders.

Yohimbe extract primarily targets adrenergic receptors due to its active component, yohimbine, an alkaloid. It is recognized for its biological activities, including the enhancement of sexual function, potential weight loss benefits, and promotion of blood circulation. This natural extract is widely utilized in pharmacological research and studies focused on cardiovascular health and metabolic regulation.

Zuclopenthixol decanoate is an antipsychotic compound that primarily targets dopamine receptors in the central nervous system. This long-acting formulation is utilized in research focused on schizophrenia and other serious mental health disorders, offering insights into therapeutic interventions and treatment protocols. Its sustained release properties allow for improved management of symptoms, making it valuable in preclinical and clinical studies.

(R)-RS 56812 is a selective antagonist of the 5-HT3 receptor. This compound has been shown to enhance cognitive performance in primate models, particularly in tasks involving delayed matching. The (R) isomer exhibits greater efficacy in facilitating cognitive function compared to its (S) counterpart, suggesting potential therapeutic applications in conditions associated with cognitive decline.

Prostaglandin I3 sodium is a potent inhibitor of platelet aggregation, primarily acting through the stimulation of adenylate cyclase, which increases cyclic AMP levels in platelets. This compound also exhibits vasodilatory properties, making it useful in studies related to cardiovascular health and thrombotic disorders. Its applications include research into the modulation of vascular tone and the prevention of platelet-related complications in various disease models.

4-(cis)-Acetyl-3,6,8-trihydroxy-3-methyldihydronaphthalenone is a natural product derived from Senna siamea, primarily investigated for its interactions with adenosine receptors. Although it demonstrates very low affinity for the adenosine A1 receptor (Ki > 50 μM), its unique structural features may offer insights into the modulation of bioactive compounds in various biological systems. This compound can serve as a valuable tool in research exploring the pharmacological properties of natural products.

Dibutepinephrine is an orally active adrenergic prodrug that targets adrenergic receptors. It demonstrates significant efficacy in rapidly alleviating allergic symptoms, making it a valuable tool for studying severe allergic reactions. This compound is useful in research focused on the mechanisms of allergic responses and the development of therapeutic interventions.

GW-5823 is a selective agonist of the cholecystokinin A receptor (CCK-AR), exhibiting an EC50 of 70 nM. This compound plays a crucial role in modulating appetite and satiety signals, making it valuable for research focused on obesity and metabolic disorders. Its specificity allows for detailed investigations into CCK-AR-related pathways and therapeutic potentials in weight management.

[Rh(cod)Cl]2 (Chloro(1,5-cyclooctadiene)rhodium(I) dimer) functions as an anti-platelet aggregation agent by inhibiting platelet-activating factor-mediated aggregation, with IC50 values of 5.2 μM in rabbit platelets and 43.3 μM in human platelet-rich plasma. It also inhibits thrombin-, ADP-, and collagen-induced aggregation, showing IC50 values of 16.7 μM, 162 μM, and 69.8 μM, respectively. This compound is valuable for research into cardiovascular diseases, particularly thrombosis.

Arachidoyl ethanolamide is an ester derivative of arachidonic acid that functions primarily as a bioactive lipid mediator. It is known to modulate various physiological processes by interacting with cannabinoid receptors and has potential implications in pain modulation and inflammation. This compound is utilized in research to investigate endocannabinoid signaling pathways and their roles in various biological systems.

Aripiprazole Lauroxil is a long-acting injectable antipsychotic targeting dopamine receptors D2 and D4. It is an N-acyloxymethyl proagent of Aripiprazole, which undergoes enzymatic cleavage by esterases in the body to yield N-hydroxymethyl aripiprazole and lauric acid, further converting to aripiprazole and formaldehyde. This compound exhibits therapeutic activity in the management of schizophrenia and is utilized in research related to psychotropic medications and long-term treatment strategies.

GLP-1R Agonist 3 is a potent agonist of the glucagon-like peptide-1 receptor (GLP-1R). This compound, a modified imidazole derivative, plays a significant role in modulating insulin secretion and glucose homeostasis. GLP-1R Agonist 3 is primarily utilized in research focused on diabetes and metabolic disorders, offering avenues for developing novel therapeutic strategies.

Carphenazine is a phenothiazine antipsychotic agent that primarily targets dopamine receptors in the central nervous system. It exhibits significant antipsychotic activity, making it useful for studying the mechanisms underlying chronic schizophrenic psychoses. This compound is employed in research to better understand therapeutic interventions for various psychotic disorders.

Cloricromen hydrochloride is a potent platelet aggregation inhibitor that effectively targets and modulates platelet activation pathways. This compound has demonstrated the ability to inhibit platelet aggregation in both human and experimental thrombosis models, making it a valuable reagent for research into cardiovascular diseases and thrombotic disorders. Cloricromen hydrochloride is suitable for studies focused on the mechanisms of platelet function and the development of antithrombotic therapies.

SB 268262 is a selective antagonist of the calcitonin gene-related peptide (CGRP) receptor. This compound exhibits high affinity for CGRP receptors in the human brain, making it a valuable tool for studying CGRP signaling pathways. SB 268262 is applicable in research investigating the pharmacological properties of non-peptide CGRP receptor antagonists, also known as gepants, in models including rat, pig, and human meninges.

KP-10614 is a potent, orally active inhibitor of platelet aggregation, primarily targeting ADP-induced aggregation with an IC50 of 1 nM. This compound exhibits dose-dependent inhibition of ex vivo platelet aggregation in rat models. KP-10614 demonstrates significant antithrombotic effects across various thrombosis models, making it a valuable tool for research into thrombotic diseases.